



February 19, 2013 02:42 PM Eastern Daylight Time

## BioDtech, Inc. Issued New United States Patent

BIRMINGHAM, Ala.--(BUSINESS WIRE)--BioDtech, Inc., a biotechnology company engaged in the development of cutting-edge products for the endotoxin market, announced that it has been granted a patent, by the United States patent office (No. 8,349,570), protecting methods of endotoxin detection. The patent, entitled "Enhancing Endotoxin Detection," covers the company's EndoPrep™ and ESP™ technologies for the use of accurate endotoxin detection in biopharmaceuticals and human plasma, respectively.

This is the second patent issued to BioDtech for the protection of their intellectual property designed to detect Gram-negative bacteria in a sample, then remove and neutralize endotoxins, depending on their specific requirements.

"The technology covered by this patent has broad applications that enable better safety and efficacy for biotherapeutics and monitoring of inflammation based diseases," stated Dr. Michael Pepe PhD, President and Chief Executive Officer of BioDtech. "The company is currently pursuing the potential use of this technology for the quality control and production of biotherapeutics as well as diagnostic monitoring of gastrointestinal diseases and Gram-negative bacterial infections," added Pepe.

**"The technology covered by this patent has broad applications that enable better safety and efficacy for biotherapeutics and monitoring of inflammation based diseases"**

### About BioDtech, Inc.

BioDtech, Inc. was founded in 2003 to accelerate the development of technologically advanced products for the endotoxin market. It develops and markets a line of reagents and systems globally for the detection, neutralization and removal of endotoxin in injectable drugs, pharmaceutical grade water, medical devices, environmental samples and surfaces. BioDtech's goal is to monitor endotoxin in the progression of multiple disease states related to inflammation.

BioDtech has a license agreement with the [National University of Singapore](#) for the exclusive worldwide licensing rights to develop specific research products and technology as related to endotoxin detection, neutralization and removal. It also has strategic partnerships with biopharmaceutical, pharmaceutical and medical device companies that utilize BioDtech technology with their existing portfolio of products.

For more information about BioDtech, visit <http://www.biodtechinc.com>.

### Contacts

Panorama Public Relations  
Darlene Rotch, 205-328-9334  
[darlene@prview.com](mailto:darlene@prview.com)

